E-cigarette, or Vaping, Product Use-Associated Lung Injury: Looking Back, Moving Forward

Area of Science:

• Public Health
• Epidemiology
• Toxicology

Background:

• The 2019 outbreak of e-cigarette, or vaping, product use associated lung injury (EVALI) presented a significant public health challenge.
• Identifying the primary causative agent was critical for effective intervention and control.

Purpose of the Study:

• To describe the evidence-based methodology used to determine the cause of the EVALI outbreak.
• To outline strategies employed to curb the 2019 epidemic.
• To discuss future research directions and public health practices for EVALI prevention.

Main Methods:

• Systematic review of clinical data, epidemiological investigations, and laboratory analyses.
• Collaboration between public health agencies, healthcare providers, and researchers.
• Utilizing a multi-pronged approach to investigate potential etiologies.

Main Results:

• Vitamin E acetate in vaping products was identified as the primary cause of EVALI.
• Public health interventions, including product restrictions and public awareness campaigns, contributed to the decline in EVALI cases.
• The outbreak highlighted the importance of robust surveillance and rapid response systems.

Conclusions:

• An evidence-based, multi-disciplinary approach was effective in identifying the cause of EVALI and managing the outbreak.
• Continued research is needed to understand the long-term health effects of vaping and to inform prevention strategies.
• Public health practice must remain vigilant to prevent future outbreaks of vaping-associated lung injuries.